{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:12Z","timestamp":1791920052495,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00198-021-06095-y","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T12:03:48Z","timestamp":1629893028000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-3235","authenticated-orcid":false,"given":"S.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-5950","authenticated-orcid":false,"given":"S.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3235-7197","authenticated-orcid":false,"given":"S.","family":"Khasbage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-2774","authenticated-orcid":false,"given":"T.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-5279","authenticated-orcid":false,"given":"J.","family":"Sachin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-9961","authenticated-orcid":false,"given":"J.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7163-0400","authenticated-orcid":false,"given":"S B","family":"Varthya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"6095_CR1","doi-asserted-by":"crossref","unstructured":"Osteoporosis prevention, diagnosis, and therapy (2001). Jama 285 785\u2013795","DOI":"10.1001\/jama.285.6.785"},{"key":"6095_CR2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet (London, England) 377:1276\u20131287","journal-title":"Lancet (London, England)"},{"key":"6095_CR3","unstructured":"The International Osteoporosis Foundation (IOF) (2020) Facts & statistics. https:\/\/www.osteoporosis.foundation\/facts-statistics Accessed Dec 12 2020"},{"key":"6095_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J, Cooper C, Stenmark J, McCloskey EV, J\u00f6nsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"6095_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet (London, England) 393:364\u2013376","journal-title":"Lancet (London, England)"},{"key":"6095_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 374:254\u2013262","journal-title":"N Engl J Med"},{"key":"6095_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N et al (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537\u2013543","journal-title":"Hum Mol Genet"},{"key":"6095_CR8","doi-asserted-by":"publisher","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","volume":"285","author":"C Krause","year":"2010","unstructured":"Krause C, Korchynskyi O, de Rooij K et al (2010) Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614\u201341626","journal-title":"J Biol Chem"},{"key":"6095_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Gardner JC, Van Ness J et al (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577\u2013589","journal-title":"Am J Hum Genet"},{"key":"6095_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, on behalf of the Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis Foundation (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"6095_CR11","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"6095_CR12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DDDT.S127568","volume":"11","author":"SY Lim","year":"2017","unstructured":"Lim SY, Bolster MB (2017) Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Dev Ther 11:1221\u20131231","journal-title":"Drug Des Dev Ther"},{"key":"6095_CR13","unstructured":"EVENITY 105 mg solution for injection in pre-filled pen Pharmacodynamic properties. https:\/\/www.medicines.org.uk\/emc\/product\/10956#PHARMACODYNAMIC_PROPS Accessed Dec 12 2020"},{"key":"6095_CR14","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"6095_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant HK, Engelke K, Bolognese MA et al (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32:181\u2013187","journal-title":"J Bone Miner Res"},{"key":"6095_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215","journal-title":"Bone"},{"key":"6095_CR17","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet (London, England) 390:1585\u20131594","journal-title":"Lancet (London, England)"},{"key":"6095_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"6095_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219\u20131226","journal-title":"J Bone Miner Res"},{"key":"6095_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline Update. J Clin Endocrinol Metab 105:587\u2013594","journal-title":"J Clin Endocrinol Metab"},{"key":"6095_CR21","first-page":"i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical research ed) 355:i4919","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"6095_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT (2020) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361","journal-title":"Res Synth Methods"},{"key":"6095_CR23","unstructured":"Cochrane Training Cochrane Review Manager (RevMan). https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman Accessed Dec 12 2020"},{"key":"6095_CR24","unstructured":"Cochrane Training Cochrane Handbook for Systematic Reviews of Interventions. https:\/\/training.cochrane.org\/cochrane-handbook-systematic-reviews-interventions Accessed Dec 12 2020"},{"key":"6095_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327:557\u2013560","journal-title":"BMJ (Clinical research ed)"},{"key":"6095_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982\u2013989","journal-title":"Ann Intern Med"},{"key":"6095_CR27","unstructured":"Holger Sch\u00fcnemann JB, Gordon Guyatt, Andrew Oxman GRADE Handbook. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.hnedbo8gqjqk Accessed Dec 12 2020"},{"key":"6095_CR28","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). (2018). A randomized phase 3 study to evaluate two formulations of romosozumab in postmenopausal women with osteoporosis. Identifier: NCT02016716. Retrieved 10 October, 2020 from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02016716"},{"key":"6095_CR29","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). (2019). A safety and efficacy study to evaluate romosozumab (AMG 785) in South Korean women with osteoporosis. Identifier: NCT02791516. Retrieved 10 October, 2020 from https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02791516"},{"key":"6095_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","volume":"54","author":"D Padhi","year":"2014","unstructured":"Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54:168\u2013178","journal-title":"J Clin Pharmacol"},{"key":"6095_CR31","first-page":"195","volume":"378","author":"KG Saag","year":"2018","unstructured":"Saag KG, Petersen J, Grauer A (2018) Romosozumab versus Alendronate and Fracture risk in women with osteoporosis. N Engl J Med 378:195\u2013196","journal-title":"N Engl J Med"},{"key":"6095_CR32","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193","journal-title":"J Clin Endocrinol Metab"},{"key":"6095_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension Study. J Bone Miner Res 34:419\u2013428","journal-title":"J Bone Miner Res"},{"key":"6095_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"6095_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2106\/JBJS.19.00790","volume":"102","author":"EH Schemitsch","year":"2020","unstructured":"Schemitsch EH, Miclau T, Karachalios T et al (2020) A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am 102:693\u2013702","journal-title":"J Bone Joint Surg Am"},{"key":"6095_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","volume":"21","author":"Y Liu","year":"2018","unstructured":"Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 21:189\u2013195","journal-title":"Climacteric"},{"key":"6095_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.maturitas.2019.08.003","volume":"129","author":"AV Hernandez","year":"2019","unstructured":"Hernandez AV, P\u00e9rez-L\u00f3pez FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A (2019) Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials. Maturitas 129:12\u201322","journal-title":"Maturitas"},{"key":"6095_CR38","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"6095_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.afos.2020.02.003","volume":"6","author":"L M\u00f6ckel","year":"2020","unstructured":"M\u00f6ckel L, Bartneck M, M\u00f6ckel C (2020) Risk of falls in postmenopausal women treated with romosozumab: preliminary indices from a meta-analysis of randomized, controlled trials. Osteoporosis Sarcopenia 6:20\u201326","journal-title":"Osteoporosis Sarcopenia"},{"key":"6095_CR40","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"S Kaveh","year":"2020","unstructured":"Kaveh S, Hosseinifard H, Ghadimi N, Vojdanian M, Aryankhesal A (2020) Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol 39:3261\u20133276","journal-title":"Clin Rheumatol"},{"key":"6095_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/aoj.2019.12.07","volume":"5","author":"W Chen","year":"2020","unstructured":"Chen W, Yang H, Jiang XJAoJ, (2020) Effects of romosozumab on low bone mineral density or osteoporosis in postmenopausal women: a systematic review. Ann Joint 5:18\u201318","journal-title":"Ann Joint"},{"key":"6095_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/mab.2019.0049","volume":"39","author":"G Mariscal","year":"2020","unstructured":"Mariscal G, Nu\u00f1ez JH, Bhatia S, Barrios C, Domenech-Fern\u00e1ndez P (2020) Safety of romosozumab in osteoporotic men and postmenopausal women: a meta-analysis and systematic review. Monoclonal antibodies in immunodiagnosis and immunotherapy 39:29\u201336","journal-title":"Monoclonal antibodies in immunodiagnosis and immunotherapy"},{"key":"6095_CR43","unstructured":"EVENITY\u2122 (romosozumab-aqqg) (2019) Prescribing information: Romosozumab. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761062s000lbl.pdf Accessed Dec 12 2020"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06095-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06095-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06095-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T14:14:47Z","timestamp":1642083287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06095-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6095"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06095-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}